食管癌化疗及生物标志物的最新进展
Recent progress of chemotherapy and biomarkers for gastroesophageal cancer.
作者信息
Maeda Osamu, Ando Yuichi
机构信息
Department of Clinical Oncology and Chemotherapy, Nagoya University Hospital, Nagoya 466-8560, Japan.
出版信息
World J Gastrointest Oncol. 2019 Jul 15;11(7):518-526. doi: 10.4251/wjgo.v11.i7.518.
Abstract
Key cytotoxic drugs of chemotherapy for gastroesophageal cancer include fluoropyrimidine, platinum, taxanes and irinotecan. Concurrent chemoradiotherapy is one of the main treatment strategies, especially for esophageal cancer. As molecular target agents, the anti-HER2 antibody trastuzumab for HER2-positive gastric cancer and the anti-angiogenesis agent ramucirumab combined with paclitaxel have been proven to improve the survival of gastric cancer patients. Recently, anti-PD-1 antibodies have become available as second- or later-line chemotherapy. Microsatellite instability is also useful as a biomarker to select patients suitable for immunotherapy. Furthermore, genome-wide analysis has improved our understanding of the biological features and molecular mechanisms of gastroesophageal cancer and will provide optimized treatment selection.
摘要
食管癌化疗的关键细胞毒性药物包括氟嘧啶、铂类、紫杉烷类和伊立替康。同步放化疗是主要治疗策略之一，尤其是对于食管癌。作为分子靶向药物，抗HER2抗体曲妥珠单抗用于HER2阳性胃癌，抗血管生成药物雷莫西尤单抗联合紫杉醇已被证明可提高胃癌患者的生存率。最近，抗PD-1抗体已作为二线或更后线化疗药物可用。微卫星不稳定性也可作为一种生物标志物，用于选择适合免疫治疗的患者。此外，全基因组分析提高了我们对食管癌生物学特征和分子机制的认识，并将提供优化的治疗选择。
相似文献
1
Recent progress of chemotherapy and biomarkers for gastroesophageal cancer.食管癌化疗及生物标志物的最新进展
World J Gastrointest Oncol. 2019 Jul 15;11(7):518-526. doi: 10.4251/wjgo.v11.i7.518.
2
Clinical Management of Gastric Cancer Treatment Regimens.胃癌治疗方案的临床管理。
Curr Top Microbiol Immunol. 2023;444:279-304. doi: 10.1007/978-3-031-47331-9_11.
3
Influence of Taxanes on Treatment Sequence in Gastric Cancer.紫杉烷类药物对胃癌治疗顺序的影响。
Oncol Res Treat. 2020;43(1-2):42-47. doi: 10.1159/000503428. Epub 2019 Oct 21.
4
Evolving therapies in advanced oesophago-gastric cancers and the increasing role of immunotherapy.晚期食管胃结合部癌的治疗进展和免疫治疗的作用日益凸显。
Expert Rev Anticancer Ther. 2021 May;21(5):535-546. doi: 10.1080/14737140.2021.1866548. Epub 2021 Jan 11.
5
Ramucirumab: targeting angiogenesis in the treatment of gastric cancer.雷莫西尤单抗：靶向血管生成用于治疗胃癌
Immunotherapy. 2014;6(11):1177-86. doi: 10.2217/imt.14.85.
6
Assessment of Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in patients with advanced HER-2 negative gastric or gastroesophageal junction cancers: the ARMANI phase III trial.评估雷莫芦单抗联合紫杉醇作为二线维持治疗与一线化疗在 HER-2 阴性晚期胃或胃食管交界处癌患者中的疗效：ARMANI Ⅲ期临床试验。
BMC Cancer. 2019 Mar 29;19(1):283. doi: 10.1186/s12885-019-5498-3.
7
Advancing pharmacological treatment options for advanced gastric cancer.推进晚期胃癌的药物治疗方案
Expert Opin Pharmacother. 2015;16(15):2293-305. doi: 10.1517/14656566.2015.1080238. Epub 2015 Sep 11.
8
EORTC-1203-GITCG - the "INNOVATION"-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group.EORTC-1203-GITCG - “创新”试验：曲妥珠单抗单药与曲妥珠单抗加帕妥珠单抗联合化疗在 HER2 阳性胃和胃食管交界处腺癌围手术期治疗中的疗效对比：EORTC 胃肠道肿瘤研究组、韩国癌症研究组和荷兰上消化道肿瘤组的一项随机 II 期分组试验。
BMC Cancer. 2019 May 24;19(1):494. doi: 10.1186/s12885-019-5675-4.
9
Overview of Chemotherapy for Gastric Cancer.胃癌化疗概述
J Clin Med. 2023 Feb 7;12(4):1336. doi: 10.3390/jcm12041336.
10
Targetting esophageal and gastric cancers with monoclonal antibodies.用单克隆抗体靶向治疗食管癌和胃癌。
Curr Top Med Chem. 2012;12(15):1678-82. doi: 10.2174/156802612803531360.
引用本文的文献
1
NDUFC1 Is Upregulated in Gastric Cancer and Regulates Cell Proliferation, Apoptosis, Cycle and Migration.NDUFC1在胃癌中上调并调节细胞增殖、凋亡、周期和迁移。
Front Oncol. 2021 Dec 13;11:709044. doi: 10.3389/fonc.2021.709044. eCollection 2021.
2
CHSY1 is upregulated and acts as tumor promotor in gastric cancer through regulating cell proliferation, apoptosis, and migration.CHSY1 在胃癌中上调并发挥肿瘤促进作用，通过调节细胞增殖、凋亡和迁移。
Cell Cycle. 2021 Sep;20(18):1861-1874. doi: 10.1080/15384101.2021.1963553. Epub 2021 Aug 19.
3
Mechanisms of Pharmaceutical Therapy and Drug Resistance in Esophageal Cancer.食管癌的药物治疗机制与耐药性
Front Cell Dev Biol. 2021 Feb 11;9:612451. doi: 10.3389/fcell.2021.612451. eCollection 2021.
4
The Anti-PD-1/PD-L1 Immunotherapy for Gastric Esophageal Cancer: A Systematic Review and Meta-Analysis and Literature Review.抗PD-1/PD-L1免疫疗法治疗胃食管癌：系统评价与Meta分析及文献综述
Cancer Control. 2021 Jan-Dec;28:1073274821997430. doi: 10.1177/1073274821997430.
5
FISH and Chromosome Microarray Testing of Gastroesophageal Adenocarcinomas at a Single Institution.单机构胃食管腺癌的荧光原位杂交及染色体微阵列检测
Cancer Med J. 2020;3(Suppl 1):39-46. Epub 2020 Nov 7.
本文引用的文献
1
A seven-Gene Signature assay improves prognostic risk stratification of perioperative chemotherapy treated gastroesophageal cancer patients from the MAGIC trial.一项七基因标志物检测分析可改善 MAGIC 试验中接受围手术期化疗的胃食管癌患者的预后风险分层。
Ann Oncol. 2018 Dec 1;29(12):2356-2362. doi: 10.1093/annonc/mdy407.
2
Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial.替氟尿苷/替匹嘧啶对比安慰剂用于既往大量治疗的转移性胃癌患者（TAGS）：一项随机、双盲、安慰剂对照的 3 期临床试验。
Lancet Oncol. 2018 Nov;19(11):1437-1448. doi: 10.1016/S1470-2045(18)30739-3. Epub 2018 Oct 21.
3
A phase II study of neoadjuvant chemotherapy with docetaxel, cisplatin, and S-1, followed by gastrectomy with D2 lymph node dissection for high-risk advanced gastric cancer: results of the KDOG1001 trial.一项新辅助化疗联合多西他赛、顺铂和 S-1，继以 D2 淋巴结清扫术治疗高危进展期胃癌的 II 期研究：KDOG1001 试验结果。
Gastric Cancer. 2019 May;22(3):598-606. doi: 10.1007/s10120-018-0884-0. Epub 2018 Oct 3.
4
Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study.帕妥珠单抗联合曲妥珠单抗和化疗治疗人表皮生长因子受体 2 阳性转移性胃或胃食管交界腺癌（JACOB）：一项双盲、随机、安慰剂对照的 3 期研究的最终分析。
Lancet Oncol. 2018 Oct;19(10):1372-1384. doi: 10.1016/S1470-2045(18)30481-9. Epub 2018 Sep 11.
5
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial.帕博利珠单抗对比紫杉醇用于治疗晚期或胃食管结合部腺癌（KEYNOTE-061）：一项随机、开放标签、对照、III 期临床试验。
Lancet. 2018 Jul 14;392(10142):123-133. doi: 10.1016/S0140-6736(18)31257-1. Epub 2018 Jun 4.
6
Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial.帕博利珠单抗单药治疗既往治疗的晚期胃和胃食管结合部癌患者的安全性和疗效：Ⅱ期 KEYNOTE-059 临床试验。
JAMA Oncol. 2018 May 10;4(5):e180013. doi: 10.1001/jamaoncol.2018.0013.
7
Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial.纳武利尤单抗治疗既往至少两种化疗方案治疗失败或不耐受的晚期胃或胃食管结合部腺癌患者（ONO-4538-12，ATTRACTION-2）：一项随机、双盲、安慰剂对照、III 期临床试验。
Lancet. 2017 Dec 2;390(10111):2461-2471. doi: 10.1016/S0140-6736(17)31827-5. Epub 2017 Oct 6.
8
Capecitabine, 5-fluorouracil and S-1 based regimens for previously untreated advanced oesophagogastric cancer: A network meta-analysis.卡培他滨、氟尿嘧啶和 S-1 为基础的方案治疗未经治疗的晚期胃食管交界癌：一项网络荟萃分析。
Sci Rep. 2017 Aug 2;7(1):7142. doi: 10.1038/s41598-017-07750-3.
9
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.错配修复缺陷可预测实体瘤对程序性死亡受体1（PD-1）阻断疗法的反应。
Science. 2017 Jul 28;357(6349):409-413. doi: 10.1126/science.aan6733. Epub 2017 Jun 8.
10
Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study.曲妥珠单抗-美坦新偶联物对比紫杉烷类药物用于既往治疗的人表皮生长因子受体 2（HER2）阳性局部晚期或转移性胃或胃食管结合部腺癌（GATSBY）：一项国际、随机、开放标签、适应性、2/3 期研究。
Lancet Oncol. 2017 May;18(5):640-653. doi: 10.1016/S1470-2045(17)30111-0. Epub 2017 Mar 23.
Zotero 插件